Metastatic Lung Cancer - Pipeline Review, H2 2012 New Report
Metastatic Lung Cancer - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Lung Cancer. Metastatic Lung Cancer - Pipeline Review, Half Year is built using data and information sourced from databases, Company/University websites, SEC filings, investor presentations and featured press...
View full press release